Edition:
India

Almirall Revises FY 2020 Guidance To Include COVID-19 Impact


Monday, 27 Jul 2020 

July 27 (Reuters) - Almirall SA ::THE GROUP'S PRODUCTION ACTIVITIES HAVE NOT BEEN DISRUPTED DURING PANDEMIC AND THE SUPPLY OF MEDICINES HAS BEEN CARRIED OUT AS NORMAL.DESPITE NOT DISRUPTING PRODUCTION ACTIVITY, GROUP'S SALES HAVE BEEN NEGATIVELY IMPACTED AS RESULT OF GLOBAL ECONOMY, AS WELL AS BY RESTRICTION OF PEOPLE MOBILITY.SAYS WITH RESPECT TO VALUATION OF INVENTORIES, THERE HAS BEEN NO PROVISION FOR SLOW ROTATION OR EXPIRATION RELATED TO COVID-19.FROM A LIQUIDITY POINT OF VIEW, COVID-19 HAS NOT HAD A SIGNIFICANT IMPACT ON THE GROUP.FY 2020 GUIDANCE REVISED TO INCLUDE COVID-19 IMPACT.SEES 2020 NET SALES OF LOW TO MID-SINGLE-DIGIT DECLINE, REVISED FROM LOW TO MID-SINGLE-DIGIT GROWTH .SEES 2020 EBITDA OF BETWEEN 230-250 MILLION EUROS, REVISED FROM BETWEEN 260-280 MILLION EUROS.